000856585 001__ 856585
000856585 005__ 20210129235324.0
000856585 0247_ $$2doi$$a10.1007/s00259-018-4188-8
000856585 0247_ $$2pmid$$apmid:30327856
000856585 0247_ $$2WOS$$aWOS:000457151600007
000856585 0247_ $$2Handle$$a2128/23175
000856585 037__ $$aFZJ-2018-05959
000856585 082__ $$a610
000856585 1001_ $$0P:(DE-Juel1)145110$$aLohmann, P.$$b0$$eCorresponding author$$ufzj
000856585 245__ $$aFET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
000856585 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2019
000856585 3367_ $$2DRIVER$$aarticle
000856585 3367_ $$2DataCite$$aOutput Types/Journal article
000856585 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1572424132_28663
000856585 3367_ $$2BibTeX$$aARTICLE
000856585 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000856585 3367_ $$00$$2EndNote$$aJournal Article
000856585 520__ $$aPurposeAreas of contrast enhancement (CE) on MRI are usually the target for resection or radiotherapy target volume definition in glioblastomas. However, the solid tumour mass may extend beyond areas of CE. Amino acid PET can detect parts of the tumour that show no CE. We systematically investigated tumour volumes delineated by amino acid PET and MRI in patients with newly diagnosed, untreated glioblastoma.MethodsPreoperatively, 50 patients with neuropathologically confirmed glioblastoma underwent O-(2-[18F]-fluoroethyl)-l-tyrosine (FET) PET, and fluid-attenuated inversion recovery (FLAIR) and contrast-enhanced MRI. Areas of CE were manually segmented. FET PET tumour volumes were segmented using a tumour-to-brain ratio of ≥1.6. The percentage overlap volumes, and Dice and Jaccard spatial similarity coefficients (DSC, JSC) were calculated. FLAIR images were evaluated visually.ResultsIn 43 patients (86%), the FET tumour volume was significantly larger than the CE volume (21.5 ± 14.3 mL vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients (80%) showed both increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET uptake and CE was low (mean DSC 0.39 ± 0.21, mean JSC 0.26 ± 0.16). Ten patients (20%) showed no CE, and one of these patients showed no FET uptake. In five patients (10%), increased FET uptake was present outside areas of FLAIR hyperintensity.ConclusionOur results show that the metabolically active tumour volume delineated by FET PET is significantly larger than tumour volume delineated by CE. Furthermore, the results strongly suggest that the information derived from both imaging modalities should be integrated into the management of patients with newly diagnosed glioblastoma.
000856585 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000856585 7001_ $$0P:(DE-HGF)0$$aStavrinou, P.$$b1
000856585 7001_ $$0P:(DE-HGF)0$$aLipke, K.$$b2
000856585 7001_ $$0P:(DE-HGF)0$$aBauer, E. K.$$b3
000856585 7001_ $$0P:(DE-HGF)0$$aCeccon, G.$$b4
000856585 7001_ $$0P:(DE-HGF)0$$aWerner, J. M.$$b5
000856585 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, B.$$b6$$ufzj
000856585 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b7$$ufzj
000856585 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b8$$ufzj
000856585 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b9$$ufzj
000856585 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b10$$ufzj
000856585 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-018-4188-8$$n3$$p591-602$$tEuropean journal of nuclear medicine and molecular imaging$$v46$$x0340-6997$$y2019
000856585 8564_ $$uhttps://juser.fz-juelich.de/record/856585/files/Lohmann2019_Article_FETPETRevealsConsiderableSpati.pdf$$yRestricted
000856585 8564_ $$uhttps://juser.fz-juelich.de/record/856585/files/57229A88-1.pdf$$yOpenAccess
000856585 8564_ $$uhttps://juser.fz-juelich.de/record/856585/files/Lohmann2019_Article_FETPETRevealsConsiderableSpati.pdf?subformat=pdfa$$xpdfa$$yRestricted
000856585 909CO $$ooai:juser.fz-juelich.de:856585$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b0$$kFZJ
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b6$$kFZJ
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b9$$kFZJ
000856585 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
000856585 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000856585 9141_ $$y2019
000856585 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000856585 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000856585 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000856585 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2017
000856585 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000856585 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000856585 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000856585 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000856585 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000856585 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2017
000856585 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000856585 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000856585 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000856585 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000856585 920__ $$lyes
000856585 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000856585 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000856585 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000856585 980__ $$ajournal
000856585 980__ $$aVDB
000856585 980__ $$aUNRESTRICTED
000856585 980__ $$aI:(DE-Juel1)INM-3-20090406
000856585 980__ $$aI:(DE-Juel1)INM-4-20090406
000856585 980__ $$aI:(DE-Juel1)INM-5-20090406
000856585 9801_ $$aFullTexts